Form 4 for KYMR Kymera Therapeutics, Inc.
Accepted 2026-04-10 16:45:41 ET · period of report 2026-04-09 · accession 0001193125-26-151393 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-04-10 16:45 | 2026-04-09 | KYMR | Goodman Noah | Chief Business Off | M - OptEx | $21.05 | +2,500 | 61.8K | +4% | +$52.6K |
| DMT | 2026-04-10 16:45 | 2026-04-09+ | KYMR | Goodman Noah | Chief Business Off | S - Sale+OE | $87.47 | -10.3K | 51.5K | -17% | -$897.8K |
| DT | 2026-04-10 16:45 | 2026-04-09 | KYMR | Goodman Noah | Chief Business Off | M - OptEx | $0.00 | -2,500 | 97.5K | -2% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-04-09 | M | A | 2,500 | $21.05 | 61,806.44 | D | — | — | (F1) These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025 adopted by the reporting person. |
| 2 | Common | Common Stock | 2026-04-09 | S | D | 3,094 | $86.62 | 58,712.44 | D | — | — | (F2) Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. Such sales were automatic and not in the discretion of the reporting person. (F3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $86.005 to $86.935, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 3 | Common | Common Stock | 2026-04-09 | S | D | 2,670 | $87.11 | 56,042.44 | D | — | — | (F2) Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. Such sales were automatic and not in the discretion of the reporting person. (F4) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.015 to $87.45, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 4 | Common | Common Stock | 2026-04-09 | S | D | 2,500 | $89.00 | 53,542.44 | D | — | — | (F1) These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025 adopted by the reporting person. |
| 5 | Common | Common Stock | 2026-04-10 | S | D | 2,000 | $87.35 | 51,542.44 | D | — | — | (F1) These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025 adopted by the reporting person. |
| 6 | Derivative | Stock Option (Right to Buy) | 2026-04-09 | M | D | 2,500 | $0.00 | 97,500 | D | $21.05 · — to 2035-04-07 | 2,500 Common Stock | (F1) These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025 adopted by the reporting person. (F5) Twenty-five percent (25%) of the shares underlying this stock option vested on April 8, 2026, with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the reporting person's continued employment through each vesting date. |